Document is current
Any future updates will be listed below
-
Authors
Lin, Kevin H.
Rutter, Justine C. https://orcid.org/0000-0002-0851-0887
Xie, Abigail
Killarney, Shane T.
Vaganay, Camille
Benaksas, Chaima
Ling, Frank
Sodaro, Gaetano
Meslin, Paul-Arthur
Bassil, Christopher F.
Fenouille, Nina
Hoj, Jacob https://orcid.org/0000-0003-3298-3083
Washart, Rachel
Ang, Hazel X.
Cerda-Smith, Christian https://orcid.org/0000-0001-8123-5300
Chaintreuil, Paul
Jacquel, Arnaud
Auberger, Patrick
Forget, Antoine
Itzykson, Raphael https://orcid.org/0000-0003-2139-6262
Lu, Min https://orcid.org/0000-0002-8106-0587
Lin, Jiaxing
Pierobon, Mariaelena
Sheng, Zhecheng
Li, Xinghai
Chilkoti, Ashutosh
Owzar, Kouros
Rizzieri, David A. https://orcid.org/0000-0001-9886-5771
Pardee, Timothy S.
Benajiba, Lina
Petricoin, Emanuel
Puissant, Alexandre https://orcid.org/0000-0002-3997-9282
Wood, Kris C. https://orcid.org/0000-0002-5887-2253
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (F30CA206348, R01CA207083)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (GM007171, GM007171, GM007171, GM007171)
U.S. Department of Health & Human Services | National Institutes of Health (K00CA245732-04, F30CA247323)
- License Information
-
More Information
Article History
Received: 18 July 2021
Accepted: 4 May 2022
First Online: 6 June 2022
Competing interests
: K.C.W. is a founder, consultant and equity holder at Tavros Therapeutics and Celldom and has performed consulting work for Guidepoint Global, Bantam Pharmaceuticals and Apple Tree Partners. T.S. Pardee has received research funding from Karyopharm and has served as a paid advisor to Karyopharm. R. Itzykson has received honoraria from Karyopharm for consulting. E.P. and M.P. are inventors on patent applications that cover aspects of the reverse-phase protein microarray; as inventors, they are entitled to receive royalties as provided by US Law and George Mason University policy. E.P. and M.P. receive royalties from and are consultants of TheraLink Technologies. E.P. is a shareholder of TheraLink Technologies and shareholder and consultant of Perthera. The remaining authors declare no competing interests.
